Jeff Jones
Stock Analyst at Oppenheimer
(1.74)
# 3,335
Out of 5,008 analysts
93
Total ratings
28.57%
Success rate
-8.05%
Average return
Main Sectors:
Stocks Rated by Jeff Jones
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KYMR Kymera Therapeutics | Maintains: Outperform | $53 → $63 | $56.41 | +11.68% | 6 | Oct 1, 2025 | |
| PTHS Pelthos Therapeutics | Initiates: Outperform | $50 | $27.00 | +85.19% | 1 | Sep 2, 2025 | |
| CMMB Chemomab Therapeutics | Maintains: Outperform | $10 → $25 | $3.10 | +706.45% | 9 | Aug 27, 2025 | |
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Outperform | $56 → $53 | $14.52 | +265.01% | 10 | Aug 6, 2025 | |
| AVBP ArriVent BioPharma | Maintains: Outperform | $39 → $44 | $19.25 | +128.57% | 3 | Jun 24, 2025 | |
| ALMS Alumis | Maintains: Outperform | $26 → $25 | $4.40 | +468.18% | 3 | May 15, 2025 | |
| ZURA Zura Bio | Maintains: Outperform | $19 → $17 | $4.22 | +302.84% | 4 | May 9, 2025 | |
| CRVS Corvus Pharmaceuticals | Reiterates: Outperform | $15 → $17 | $6.76 | +151.48% | 5 | May 9, 2025 | |
| IMCR Immunocore Holdings | Maintains: Outperform | $85 → $86 | $34.32 | +150.58% | 2 | May 8, 2025 | |
| EVH Evolent Health | Maintains: Outperform | $28 → $18 | $8.00 | +125.00% | 4 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $5.00 | - | 5 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $22 → $16 | $3.48 | +360.43% | 7 | Nov 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $10 → $9 | $3.92 | +129.59% | 10 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 → $45 | $1.48 | +2,950.85% | 6 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $20.66 | - | 4 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $1.29 | - | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $5.16 | - | 2 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $15 | $1.39 | +983.03% | 5 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $75 | $0.49 | +15,341.63% | 2 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $1,600 → $1,100 | $5.82 | +18,800.34% | 2 | Nov 17, 2022 |
Kymera Therapeutics
Oct 1, 2025
Maintains: Outperform
Price Target: $53 → $63
Current: $56.41
Upside: +11.68%
Pelthos Therapeutics
Sep 2, 2025
Initiates: Outperform
Price Target: $50
Current: $27.00
Upside: +85.19%
Chemomab Therapeutics
Aug 27, 2025
Maintains: Outperform
Price Target: $10 → $25
Current: $3.10
Upside: +706.45%
Corbus Pharmaceuticals Holdings
Aug 6, 2025
Maintains: Outperform
Price Target: $56 → $53
Current: $14.52
Upside: +265.01%
ArriVent BioPharma
Jun 24, 2025
Maintains: Outperform
Price Target: $39 → $44
Current: $19.25
Upside: +128.57%
Alumis
May 15, 2025
Maintains: Outperform
Price Target: $26 → $25
Current: $4.40
Upside: +468.18%
Zura Bio
May 9, 2025
Maintains: Outperform
Price Target: $19 → $17
Current: $4.22
Upside: +302.84%
Corvus Pharmaceuticals
May 9, 2025
Reiterates: Outperform
Price Target: $15 → $17
Current: $6.76
Upside: +151.48%
Immunocore Holdings
May 8, 2025
Maintains: Outperform
Price Target: $85 → $86
Current: $34.32
Upside: +150.58%
Evolent Health
Jan 24, 2025
Maintains: Outperform
Price Target: $28 → $18
Current: $8.00
Upside: +125.00%
Dec 11, 2024
Downgrades: Perform
Price Target: n/a
Current: $5.00
Upside: -
Nov 22, 2024
Maintains: Outperform
Price Target: $22 → $16
Current: $3.48
Upside: +360.43%
Nov 8, 2024
Reiterates: Outperform
Price Target: $10 → $9
Current: $3.92
Upside: +129.59%
Aug 8, 2024
Maintains: Outperform
Price Target: $48 → $45
Current: $1.48
Upside: +2,950.85%
Jun 7, 2024
Downgrades: Perform
Price Target: n/a
Current: $20.66
Upside: -
Apr 1, 2024
Reiterates: Perform
Price Target: n/a
Current: $1.29
Upside: -
May 23, 2023
Downgrades: Perform
Price Target: n/a
Current: $5.16
Upside: -
May 11, 2023
Reiterates: Outperform
Price Target: $15
Current: $1.39
Upside: +983.03%
Mar 24, 2023
Reiterates: Outperform
Price Target: $75
Current: $0.49
Upside: +15,341.63%
Nov 17, 2022
Maintains: Outperform
Price Target: $1,600 → $1,100
Current: $5.82
Upside: +18,800.34%